Edinburgh Biosciences is pleased to provide an update on the continued progress of the Revisyon development programme as the company advances towards key clinical, scientific and regulatory milestones.
Driven by our vision to create a future where patients have a choice beyond surgery and where innovative non-invasive therapies have the potential to transform healthcare, our teams continue to work closely with researchers, clinicians, regulatory experts and industry partners to bring this exciting technology closer to patients.
Over the past year, significant progress has been made across our clinical, scientific and regulatory programmes. Interest from eye care professionals, healthcare providers and industry stakeholders continues to grow, reinforcing the need for innovative solutions that have the potential to expand treatment options and improve patient access to care.
As we move through the next phase of development, our focus remains on generating high-quality clinical evidence, completing peer review activities and progressing through the appropriate regulatory pathways required for future commercialisation.
Patient safety remains at the heart of everything we do.
While there is understandable excitement surrounding new healthcare innovations, Edinburgh Biosciences believes that the most successful medical technologies are those built upon robust science, strong clinical evidence and rigorous regulatory review. For this reason, we remain committed to ensuring every stage of the development process is completed to the highest possible standard.
“Throughout the history of medicine, the most meaningful innovations have been those that combined scientific curiosity with patient-centred responsibility. Our goal is not simply to develop new technology, but to ensure that any future treatment option is supported by rigorous evidence and delivered with the confidence of both clinicians and patients. That is why we continue to prioritise science, safety and regulatory excellence at every stage of the Revisyon programme.”
— Yiyuan Chen, Chief Scientist, Edinburgh Biosciences
Like many organisations operating within today’s medical device sector, we have experienced some of the wider regulatory challenges affecting the industry, including evolving certification pathways and capacity constraints within notified body review processes.
As a result, we have adjusted elements of our regulatory timelines, extending certain UKCA activities while accelerating work supporting our European CE approval programme. These changes reflect the realities of the current regulatory environment and our commitment to following the appropriate approval processes without compromise.
Importantly, these adjustments have not changed our long-term vision or confidence in the programme. We remain encouraged by the progress achieved to date and continue to invest in the scientific, clinical and operational activities required to support future commercial launch preparations.
Looking ahead, Edinburgh Biosciences is exploring opportunities to further expand its clinical evidence programme through collaboration with academic institutions, healthcare providers and other key stakeholders. As the evidence base continues to develop, Edinburgh Biosciences hopes to engage with healthcare stakeholders, including NHS and health technology assessment organisations, where appropriate, to better understand future pathways for patient access.
These activities are intended to strengthen the scientific evidence base, support future healthcare decision-making and ensure that any future adoption is guided by robust clinical evidence and patient benefit.
Healthcare innovation takes time, but the outcome is worth it. Every study completed, every data set reviewed and every regulatory milestone achieved brings us one step closer to our goal of delivering innovative, non-invasive healthcare solutions that may help improve the lives of patients around the world.
We would like to thank our clinicians, researchers, partners, investors and supporters for their continued confidence in Edinburgh Biosciences and our mission.
We look forward to sharing further updates as we continue progressing towards regulatory approval and future commercial launch.
Revisyon is currently under development and has not yet received regulatory approval for commercial use. Any future availability remains subject to successful completion of clinical evaluation, regulatory review and applicable approvals.